Pollock Carol, Zuk Anna, Anders Hans-Joachim, Ganji Mohammad Reza, Johnson David W, Kasiske Bertram, Langham Robyn G, Pecoits-Filho Roberto, Remuzzi Giuseppe, Rossert Jerome, Suzuki Yusuke, Tanaka Tetsuhiro, Walker Robert, Yang Chih-Wei, Bonventre Joseph V
Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Akebia Research and Development Department, Akebia Therapeutics Inc., Cambridge, Massachusetts, USA.
Kidney Int Suppl (2011). 2017 Oct;7(2):130-137. doi: 10.1016/j.kisu.2017.07.008. Epub 2017 Sep 20.
The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches, and increasing investment in the development of new therapies to limit chronic kidney disease. Key deliverables include the establishment of new regional, national, and global consortia; development of clinical trial networks; and creation of programs to support the temporary mutual movement of scientists between academia and the biotechnology and pharmaceutical sector. Other deliverables include cataloging and maintaining up-to-date records to collate progress in renal research and development, inventorying the capacity of research and clinical networks, and describing methods to ensure novel drug development.
本文的重点是确定目标以及由此产生的行动计划，相关利益方可以共同采纳这些目标和计划，以推动新的治疗方法来减缓慢性肾病的进展。具体目标包括确定可成药靶点、提高临床前和早期临床开发能力、拓宽新治疗方法的可及性，以及增加对限制慢性肾病的新疗法开发的投资。关键成果包括建立新的区域、国家和全球联盟；发展临床试验网络；创建支持科学家在学术界与生物技术和制药行业之间临时相互流动的项目。其他成果包括编目和维护最新记录以整理肾脏研发进展、盘点研究和临床网络的能力，以及描述确保新药开发的方法。
